HIZENTRA ® ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 11 | Myasthenia gravis | 1 |
11. Myasthenia gravis
Clinical trials : 332 / Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02100969 (ClinicalTrials.gov) | May 2015 | 27/3/2014 | Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis | Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis | Myasthenia Gravis | Drug: HIZENTRA ® | Mazen Dimachkie, MD | CSL Behring | Completed | 18 Years | N/A | All | 23 | Phase 2 | United States;Canada |